Dinaciclib in Treating Patients With Stage IV Melanoma

NCT00937937 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

72

Enrollment

NIH

Sponsor class

Conditions

Acral Lentiginous Melanoma
Cutaneous Nodular Melanoma
Lentigo Maligna Melanoma
Low-CSD Melanoma
Mucosal Melanoma
Recurrent Melanoma
Stage IV Cutaneous Melanoma AJCC v6 and v7

Interventions

DRUG: Dinaciclib

Sponsor

National Cancer Institute (NCI)